As of Nov 19, 2026, 1 of 2 active firms rate IMA a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IMA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.91
Range $-0.91 – $-0.91 · 1 analysts · -4% YoY
Next period, 1 analysts expect ImageneBio, Inc. to earn $-0.91 a share (range $-0.91 – $-0.91), versus $-0.95 a year earlier. Full-year consensus is $-3.37, growing to $-3.36 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering ImageneBio, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMA.
#1
Arthur He
HC Wainwright & Co. · Rank #198
Buy
$28.00+636.8% to target
Overall win rate
50%
+ Follow
#2
MF
Martin Fan
Wedbush
Sell
$2.00-47.4% to target
Coverage
—
+ Follow
#3
David Risinger
Leerink Partners
Buy
$24.00+531.6% to target
Coverage
—
+ Follow
#4
MP
Matt Phipps
William Blair
Buy
No targeton IMA
Coverage
—
+ Follow
IMA stock forecast FAQ
What is IMA's average 12-month price target?+
The 2 active firms with a live target average $15.00 for ImageneBio, Inc. over the next 12 months, ranging from a $28.00 high to a $2.00 low, as of Nov 19, 2026.
Is IMA stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IMA?+
The Street-high target is $28.00 (HC Wainwright & Co.), and the Street-low is $2.00 (Wedbush). The average of all 2 active-firm targets is $15.00.
How many active Wall Street firms cover IMA?+
2 active firms have a recognized rating on ImageneBio, Inc. as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IMA?+
Among analysts who currently cover IMA, Arthur He of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #198). Their current call is Buy with a $28.00 target.
What is ImageneBio, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.91 per share (range $-0.91 – $-0.91) across 1 analysts. Full-year EPS is projected at $-3.37, rising to $-3.36 the following year.
How much revenue is ImageneBio, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading IMA lately?+
As of Nov 19, 2026, 1 of 2 active firms rate IMA a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.